|
|
| | AZD1656 Basic information |
| Product Name: | AZD1656 | | Synonyms: | AZD 1656;AZD1656;3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide;Benzamide, 3-[[5-(1-azetidinylcarbonyl)-2-pyrazinyl]oxy]-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methyl-2-pyrazinyl)-;Hexokinase IV,Glucokinase,AZD-1656,AZD1656,G6pc,G6P,ChREBP-β,hypoglycemia,inhibit,Inhibitor,Hexokinase D,epinephrine,glucagon,antihyperglycemic;(S)-3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-((1-methoxypropan-2-yl)oxy)-N-(5-methylpyrazin-2-yl)benzamide;AZD-1656, 10 mM in DMSO;AZD-2691 | | CAS: | 919783-22-5 | | MF: | C24H26N6O5 | | MW: | 478.5 | | EINECS: | | | Product Categories: | | | Mol File: | 919783-22-5.mol |  |
| | AZD1656 Chemical Properties |
| Boiling point | 635.0±55.0 °C(Predicted) | | density | 1.336±0.06 g/cm3(Predicted) | | solubility | DMSO: Soluble: =10 mg/ml
Ethanol: Slightly soluble: 0.1-1 mg/ml | | form | Solid | | pka | 10.84±0.70(Predicted) | | color | White to off-white |
| | AZD1656 Usage And Synthesis |
| Uses | AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research[1][2][3]. | | in vivo | AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656[1]. | Animal Model: | C57BL/6 mice[1] | | Dosage: | 0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg | | Administration: | Oral gavage; daily; for 8 weeks | | Result: | Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin.
|
| | References | [1] Brian E Ford, et al. Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge. Diabetes Obes Metab. 2020 Jun 10. DOI:10.1111/dom.14111
[2] Medicinal Chemistry, et al. Design and Development of the Glucokinase Activator AZD1656. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1, 185-220.
[3] Terri Mitchard, et al. The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator. Birth Defects Res B Dev Reprod Toxicol. 2014 Apr;101(2):152-61. DOI:10.1002/bdrb.21102
[4] M. WARING. Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656[J]. MedChemComm, 2012, 3 1: 1077-1081. DOI: 10.1039/c2md20077e
|
| | AZD1656 Preparation Products And Raw materials |
|